Synergistic interactions between trastuzumab and the oral HER1/HER2-targeted tyrosine kinase inhibitor lapatinib have been observed in HER2-overexpressing cell lines15,16 and in HER2+ tumor xenograft models17. The gene discussed is ERBB2; the disease is neoplasm.